BIRC5 and ovarian cancer: The most successful results have been obtained in ovarian cancer, where DPX-Survivac, a vaccine based on the use of survivin peptides in conjunction with a DepoVaxTM adjuvant, administrated in a treatment together with cyclophosphamide, yielded favorable results in a phase I clinical trial.